The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovarian cancer does today.
The largest acquisition of a private UK biotech company on record has been announced today, as the curtain raiser to the JP Morgan global Healthcare conference, with the news that Sanofi has acquired Kymab for $1.1bn with the possibility of further $350m milestone payments.
Biotech companies on London stock markets delivered market-beating returns in 2020 and attracted new investors looking for growth in a turbulent year, according to new analysis published today by the UK BioIndustry Association (BIA) and Radnor Capital Partners.
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “We are very encouraged by the publication of the Rare Disease Framework and in particular its focus on ensuring patient access to treatments. Science continues to advance and to deliver new treatments for rare diseases where no treatment has been available before.
Steve Bates OBE, Chief Executive of the BioIndustry Association said: "Today’s deal brings much desired certainty for our sector after four years of detailed negotiation. We look forward to examining the full text in detail."
Steve Bagshaw, Chairman of FUJIFILM Diosynth Biotechnologies and the BIA COVID-19 vaccine manufacturing taskforce, were awarded the prestigious Peter Dunnill award and Richard Wilson impact award respectively, at the UK BioIndustry Association’s (BIA) 17th bioProcessUK conference, which was held virtually on the 01 and 02 December.
The BioIndustry Association's Rare Disease Industry Group (RDIG) has today launched A Rare Chance for Reform in collaboration with PwC, calling for action to ensure that patients are able to access innovative medicines for rare diseases.
Draft legislation to implement the SME R&D tax credit PAYE cap published yesterday (12 November) confirms that the Government intends to implement a targeted exemption to protect genuine companies, as proposed by the BIA.
Responding to the publication of a consultation paper on the National Institute for Health and Care Excellence (NICE) Methods following a review, Steve Bates OBE, Chief Executive of the Bioindustry Association said: